Table 2A. Correlation between PTPN13 mRNA expression level and clinical parameters (RT-PCR analysis).
| Parameter | PTPN13 | Total | % | p-value | |||
|---|---|---|---|---|---|---|---|
| ≤ 1.55 | > 1.55 | ||||||
| n | % | n | % | ||||
| Age | 0.131 | ||||||
| ≤58 years | 5 | 35.71 | 9 | 64.29 | 14 | 50.00 | |
| >58 years | 9 | 64.29 | 5 | 35.71 | 14 | 50.00 | |
| FIGO stage | 0.050 | ||||||
| 1 – 2 | 1 | 7.14 | 5 | 38.46 | 6 | 22.22 | |
| 3 – 4 | 13 | 92.86 | 8 | 61.54 | 21 | 77.78 | |
| Cytoreductive surgery | 0.007 | ||||||
| OCS | 2 | 14.29 | 9 | 64.29 | 11 | 39.29 | |
| SCS | 12 | 85.71 | 5 | 35.71 | 17 | 60.71 | |
Patients (n=28) were stratified according to the tumor PTPN13 mRNA expression (≤ or > than the median value of 1.55). PFS: progression-free survival; OS: overall survival; HR: hazard ratios; OCS: optimal cytoreductive surgery; SCS: suboptimal cytoreductive surgery.